Business
Xeris Ships One Millionth Gvoke® Unit
Updated guidelines recognize the benefits of ready-to-use glucagon Protecting all people with diabetes at risk of severe hypoglycemia remains the goal
About this update from Xeris Biopharma Holdings, Inc.
[{"type":"text","content":"\nUpdated guidelines recognize the benefits of ready-to-use glucagon\n\n\nProtecting all people with diabetes at risk of severe hypoglycemia remains the goal\n\n\n CHICAGO--(BUSINESS WIRE)--\nXeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Xeris has shipped more than one million units of Gvoke® – the company’s ready-to-use liquid glucagon for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 years and above.\n\n\n“We are proud to celebrate this major milestone of having shipped over one million units of Gvoke since its launch,” said Paul R. Edick, Xeris’ Chairman and CEO. “However, far too many people with diabetes are still left without protection against a potentially life-threatening severe low blood sugar event. Based on recently updated guidelines by the American Diabetes Association1 and others, we estimate that approximately 15 million people2 with diabetes are at increased risk of low blood sugar, a primary risk factor being on insulin, and should be carrying a ready-to-use glucagon, like Gvoke HypoPen®,” Mr. Edick continued, “We will continue to work tirelessly towards our mission of protecting as many of the 15 million as possible and call on the medical community to take responsibility to make these new standards of care your standards of practice.”\n\n\nAbout Gvoke®\n\n\nGvoke® PFS and Gvoke HypoPen® (glucagon injection), the first prescription, ready-to-use, pre-mixed, pre-measured glucagon injection, were approved by the FDA in September 2019 for use in the United States. Gvoke is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes ages 2 years and above. In August 2021, the FDA approved Gvoke® Kit, the first ready-to-use glucagon available in a single-use vial and single-use syringe kit for rescue.\n\n\nINDICATION AND IMPORTANT SAFETY INFORMATION\n\n\nGVOKE is indicated for the treatment of severe hypoglycemia in adult and pediatric patients with diabetes ages 2 years and above.\n\n\nIMPORTANT SAFETY INFORMATION\n\n\nContraindications\n\n\nGVOKE is contraindicated in patients with pheochromocytoma because of the risk of substantial increase in blood pressur...